Shares of Insmed Inc. (Nasdaq: INSM) hiked 15% to a close of 46 cents yesterday, spurred by word the biopharmaceutical company has demonstrated the bioequivalence of INS-19, the company’s recombinant human granulocyte colony stimulating factor (G-CSF).

The Department of Defense has awarded Synthetic Blood International a number of grants totaling more than $5.3 million. The funding from these grants will be used to study clinical applications for Oxycyte®, company’s perfluorocarbon therapeutic oxygen carrier.

ImmunoCellular Therapeutics has signed a research agreement with George Mason University for the development of a blood test designed to detect small cell lung cancer and pancreatic cancer using ImmunoCellular’s monoclonal antibody technology.